Business
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024 DURHAM, N.C.--(BUSINESS
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"\nData to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024\n\n\n DURHAM, N.C.--(BUSINESS WIRE)--\nPrecision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024 in Milan, Italy.\n\n\n“We look forward to the opportunity to share the latest new preclinical safety data from our PBGENE-HBV clinical candidate at the EASL Congress,” said Jeff Smith, Co-Founder and Chief Research Officer at Precision BioSciences. “The late-breaking safety data to be presented at EASL, combined with our recent pre-IND feedback from both U.S. and international Regulators, adds to the body of evidence supporting continued progression of PBGENE-HBV as we pursue the goal to be the first potentially curative gene editing program to enter the clinic for HBV. PBGENE-HBV is designed to safely eliminate cccDNA and inactivate integrated HBV DNA. As we look ahead, we remain on track to file an investigational new drug (IND) and/or clinical trial application (CTA) in 2024.”\n\n\nPresentation Details:\n\n\nTitle: Preclinical safety data for PBGENE-HBV gene editing program supports advancement to clinical trials as a potentially curative treatment for chronic hepatitis B\nAbstract Number: LB195\nPresenter: Emily Harrison, Senior Scientist - Hepatitis Research Leader, Precision Biosciences\nDate and Time: Wednesday, June 5, 2024, 8:30 AM – Saturday, June 8, 2024, 5:00 PM CEST\n\n\nAbout Hepatitis B and PBGENE-HBV:\n\n\nHepatitis B is a leading cause of morbidity in the US and death globally, with no curative options currently available for patients. In 2019, despite the availability of approved antiviral therapies, an estimated 300 million people globally and more than 1 million people in the US were estimated to have chronic hepatitis B infection. An estimated 15% to 40% of patients with HBV infections may develop complications...